Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

The decision was supported by a randomised, six-week, placebo-controlled trial involving 316 adolescent subjects.

The European Commission (EC) has approved Danish CNS specialist Lundbeck (LUND: CO) and Otsuka Europe’s Rxulti ...

Otsuka Pharmaceutical Europe and Lundbeck have announced that the European Commission has approved Rxulti (brexpiprazole) for ...

Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has approved Rxulti® (brexpiprazole) for the treatment of schizophrenia in ...

Encephalitis is a complex and often devastating condition that can leave lasting neurological damage in survivors. Despite advancements in medical science, effective treatments remain limited, and ...

Microbiotica, a clinical-stage biopharma company, has presented new data on MB097 at the AACR IO meeting held in Los Angeles. MB097 is an oral precision microbiome medicine, currently in development ...

India and the European Union (EU) are expanding and deepening their research partnership in the area of sustainable mobility, aimed at enhancing security and people-to-people contacts. The two ...